Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.6.622

Immunogenicity of 7-valent pneumococcal conjugate vaccine related to booster immunization in Korean children  

Park, So Eun (Department of Pediatrics, College of Medicine, Pochon CHA University)
Lee, Hyunju (Department of Pediatrics, School of Medicine, Ewha Womans University)
Lim, Soo Young (Center for Vaccine Evaluation and Study, Ewha Medical Research Institute)
Kim, Kyung Hyo (Department of Pediatrics, School of Medicine, Ewha Womans University)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.6, 2008 , pp. 622-628 More about this Journal
Abstract
Purpose : The purpose of this study was to evaluate the immunogenicity of the booster immunization with pneumococcal conjugate vaccine in Korean children. Methods : Thirty-nine children aged 12-23 months who visited Kangnam CHA Hospital between September 2006 and December 2006 were enrolled. The children were divided into primary and booster groups depending on their vaccination status for the 7-valent pneumococcal conjugate vaccine. The anti-pneumococcal antibody levels of each serotype included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 23F) were determined by third-generation ELISA. Results : The geometric mean titer (GMT) of antibodies to each pneumococcal serotype in the booster group was higher than in the primary group (P<.05). The percentage of subjects with pneumococcal antibodies ${\geq}0.35{\mu}g/mL$ was 90.5-100% for all serotypes in both the primary and booster groups. The percentage of subjects with pneumococcal antibodies ${\geq}1.0g/mL$ in the booster group was 94.4-100%, which was higher than the primary group except for serotypes 6B and 14 (P<.05). The percentage of subjects with pneumococcal antibodies ${\geq}5.0{\mu}g/mL$ in the booster group was 50.0-94.4% which was higher than the primary group for all serotypes (P<0.05). Conclusion : The immunogenicity of a booster dose of the pneumococcal conjugate vaccine in Korean children was high and the immunogenicity of a primary series was also relatively high. To determine the feasibility of the introduction of the pneumococcal conjugate vaccine and the appropriate schedule for Korean children, further prospective investigation of the immunogenicity of the booster immunization is needed.
Keywords
Pneumococcal vaccine; Immunization; Secondary;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21   DOI   ScienceOn
2 Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 2005;192:387-93   DOI   ScienceOn
3 Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anticapsular IgG concentration. J Infect Dis 2000;182:1553-6   DOI   ScienceOn
4 Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007;25:2518-27   DOI   ScienceOn
5 WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 2005;927:1-29
6 Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998;101:604-11   DOI   ScienceOn
7 Schuerman L, Prymula R, Henckaerts I, Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 2007; 25:1962-8   DOI   ScienceOn
8 Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005;11:S54-62   DOI   ScienceOn
9 Shao PL, Lu CY, Chang LY, Huang FY, Lee CY, Hsueh PR, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine booster in Taiwanese toddlers. J Formos Med Assoc 2006;105:542-9   DOI   ScienceOn
10 Puumalainen T, Dagan R, Wuorimaa T, Zeta-Capeding R, Lucero M, Ollgren J, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003;22:141-9
11 Hoppenbrouwers K, Kanra G, Roelants M, Ceyhan M, Vandermeulen C, Yurdakok K, et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type btetanus toxoid conjugate (PRP-T) and diphtheria-tetanusacellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine 1999;17:875-86   DOI   ScienceOn
12 Ahman H, Kayhty H, Vuorela A, Leroy O, Eskola J. Dose dependency of antibody response in infants and children to pneuococcal polysaccharides conjugated to tetanus toxoid. Vaccine 1999;17:2726-32   DOI   ScienceOn
13 Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21:3265-72   DOI   ScienceOn
14 Kim NH, Lee J, Lee SJ, Lee H, Kim KH, Park SE, et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine 2007;25:7858-65   DOI   ScienceOn
15 Golaz A, Hardy IR, Glushkevich TG, Areytchiuk EK, Deforest A, Strebel P, et al. Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: immunogenicity and adverse reactions. J Infect Dis 2000;181 Suppl 1:S203-7   DOI   ScienceOn
16 Ekstrom N, Ahman H, Verho J, Jokinen J, Vakevainen M, Kilpi T, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005;73:369-77   DOI   ScienceOn
17 O'Brien KL, Moisi J, Moulton LH, Madore D, Eick A, Reid R, et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 2007;196:104-14   DOI   ScienceOn
18 Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25:3816-26   DOI   ScienceOn
19 Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95   DOI   ScienceOn
20 Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8   DOI   ScienceOn
21 Banatvala J, Van Damme P, Van Hattum J. Boosters for hepatitis B. European Consensus Group on Hepatitis B Immunity. Lancet 2000;356:337-8
22 Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide- diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-6   DOI   ScienceOn
23 Miernyk KM, Parkinson AJ, Rudolph KM, Petersen KM, Bulkow LR, Greenberg DP, et al. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. Clin Infect Dis 2000;31:34-41   DOI   ScienceOn
24 Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001;20: 25-33   DOI   ScienceOn